Pulmonary Arterial Hypertension: Pathophysiology and Treatment

Diseases
Norris S H LanChim C Lang

Abstract

Pulmonary arterial hypertension (PAH), the first category of pulmonary hypertension, is a chronic and progressive disorder characterised by angioproliferative vasculopathy in the pulmonary arterioles, leading to endothelial and smooth muscle proliferation and dysfunction, inflammation and thrombosis. These changes increase pulmonary vascular resistance and subsequent pulmonary arterial pressure, causing right ventricular failure which leads to eventual death if untreated. The management of PAH has advanced rapidly in recent years due to improved understanding of the condition's pathophysiology, specifically the nitric oxide, prostacyclin-thromboxane and endothelin-1 pathways. Five classes of drugs targeting these pathways are now available: phosphodiesterase-5 inhibitors, soluble guanylate cyclase stimulators, prostacyclin analogues, prostacyclin receptor agonists and endothelin receptor antagonists. These developments have led to substantial improvements in mortality rate in recent decades. Recently, long-term studies have demonstrated sustained progression-free survival and have created a new paradigm of initial combination therapy. Despite these targeted therapies, PAH is still associated with significant morbidity and morta...Continue Reading

References

Jul 9, 1992·The New England Journal of Medicine·B W ChristmanJ E Loyd
Mar 15, 1991·Annals of Internal Medicine·D J StewartD Langleben
Oct 1, 1994·American Journal of Respiratory and Critical Care Medicine·K HuberB R Binder
Jun 17, 1993·The New England Journal of Medicine·A GiaidD J Stewart
Feb 1, 1996·The New England Journal of Medicine·R J BarstUNKNOWN Primary Pulmonary Hypertension Study Group
Jun 3, 1999·American Journal of Respiratory and Critical Care Medicine·R M TuderN F Voelkel
Sep 6, 2000·Nature Genetics·UNKNOWN International PPH ConsortiumR C Trembath
Jul 21, 2001·American Journal of Respiratory and Critical Care Medicine·Y HoshikawaM W Geraci
Oct 10, 2001·Clinics in Chest Medicine·P HerveG Simonneau
Mar 19, 2002·American Journal of Respiratory and Critical Care Medicine·Gerald SimonneauUNKNOWN Treprostinil Study Group
Mar 22, 2002·The New England Journal of Medicine·Lewis J RubinGerald Simonneau
Aug 2, 2002·The New England Journal of Medicine·Horst OlschewskiUNKNOWN Aerosolized Iloprost Randomized Study Group
Dec 6, 2003·Arteriosclerosis, Thrombosis, and Vascular Biology·Nicholas J Alp, Keith M Channon
Jan 22, 2004·Circulation·Rohit BudhirajaPaul M Hassoun
Sep 11, 2004·The European Respiratory Journal·M HumbertG Simonneau
Nov 27, 2004·Psychosomatic Medicine·Bernd LöweMathias M Borst
Nov 3, 2005·The European Respiratory Journal·M M HoeperJ Niedermeyer
Nov 18, 2005·The New England Journal of Medicine·Nazzareno GalièUNKNOWN Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group
May 27, 2006·American Journal of Respiratory and Critical Care Medicine·Joy D CoganWilliam C Nichols
Jan 31, 2007·Journal of Cardiovascular Pharmacology·Olivier SitbonNazzareno Galie
Mar 7, 2007·Clinics in Chest Medicine·Eric D Austin, James E Loyd
May 29, 2008·Circulation·Nazzareno GalièUNKNOWN Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies
Jan 22, 2009·European Heart Journal·Nazzareno GalièAngelo Branzi
Mar 3, 2009·The European Respiratory Journal·M M HoeperR Ewert
May 28, 2009·Circulation·Nazzareno GalièUNKNOWN Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group
Jul 9, 2009·Journal of the American College of Cardiology·Nicholas W MorrellE Kenneth Weir
Jul 9, 2009·Journal of the American College of Cardiology·Rajiv D MachadoWendy K Chung
Jul 9, 2009·Journal of the American College of Cardiology·Gérald SimonneauRogério Souza
Jul 9, 2009·Journal of the American College of Cardiology·Vallerie V McLaughlinWerner Seeger
Dec 22, 2009·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·Jagdish HiremathUNKNOWN TRUST Study Group

❮ Previous
Next ❯

Citations

Jan 25, 2020·Clinical and Experimental Hypertension : CHE·Cheng LiHongzhong Yang
Jan 30, 2020·Antioxidants·Mathews Valuparampil VargheseRuslan Rafikov
Nov 19, 2019·Critical Reviews in Clinical Laboratory Sciences·Yan ZhangYahong Li
Nov 2, 2019·Archives of Dermatological Research·Anna StochmalLidia Rudnicka
Oct 2, 2020·Molecular and Cellular Biochemistry·P Prieto-Oliveira
Mar 25, 2019·Hemodialysis International·Mehmet Eyuboglu
Jun 14, 2020·International Journal of Molecular Sciences·Maria Catalina Gomez-PuertoPeter Ten Dijke
Jun 17, 2020·Respirology : Official Journal of the Asian Pacific Society of Respirology·Abdullah M AldalaanNadeen Alharbi
Dec 2, 2020·International Journal of Molecular Sciences·Jordy M M Kocken, Paula A da Costa Martins
Feb 13, 2021·American Journal of Physiology. Heart and Circulatory Physiology·Nicholas D FriedJason D Gardner
Jan 14, 2021·Biomedicines·Kondababu KurakulaMarie-José Goumans
Mar 3, 2021·Journal of Perinatology : Official Journal of the California Perinatal Association·Ruth B SeabrookUNKNOWN Children’s Hospitals Neonatal Consortium Congenital Diaphragmatic Hernia Focus Group
May 18, 2021·Frontiers in Cardiovascular Medicine·Richard MprahQiao Weili

❮ Previous
Next ❯

Software Mentioned

SERAPHIN
PACES
COMPASS

Related Concepts

Related Feeds

Basal Ganglia Cerebrovascular Disease

Basal ganglia cerebrovascular disease is a condition where the blood vessels in the basal ganglia are damaged or malfunction. Discover the latest research on basal ganglia cerebrovascular disease here.

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Related Papers

Current Hypertension Reports
Aaron M WolfsonMardi Gomberg-Maitland
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
Eftychia DemeroutiVassilios Voudris
The Lancet. Respiratory Medicine
Marius M HoeperNazzareno Galiè
© 2022 Meta ULC. All rights reserved